EDINBURGH, Scotland--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring for people with diabetes, today announced a significant advancement in access to its products for those treating Type 2 diabetes (T2D) with basal insulin injections. The company, which pioneered CGM technology 25 years ago, has secured access to its Dexcom ONE sensor for around 100,000 T2D users in France.

苏格兰爱丁堡--（商业新闻短讯）--糖尿病患者实时连续血糖监测的全球领导者DexCom，Inc.（纳斯达克代码：DXCM）今天宣布，对于使用基础胰岛素注射治疗2型糖尿病（T2D）的患者，其产品的获得取得了重大进展。该公司是25年前CGM技术的先驱，在法国约有10万名T2D用户可以使用其Dexcom ONE传感器。

The reimbursement guidance offers people aged over two years who are on non-intensified insulin therapy (less than 3 injections a day) and whose glycaemic control is insufficient (HbA1c ≥ 8%) access to Dexcom’s life-changing technology. The French government is the first in Europe to offer full national reimbursement for Dexcom CGM technology to those treating T2D with basal injections, following other countries around the world such as the USA and New Zealand..

报销指南为两岁以上接受非强化胰岛素治疗（每天少于3次注射）且血糖控制不足（HbA1c≥8%）的人提供了使用Dexcom改变生活的技术的机会。继美国和新西兰等世界其他国家之后，法国政府是欧洲第一个向那些通过基础注射治疗T2D的患者提供Dexcom CGM技术全额国家报销的国家。。

The French reimbursement news is part of worldwide growing awareness by governments and healthcare providers of the impact that rising diagnoses of T2D have on both national healthcare services and those living with the condition. Governments and healthcare providers are increasingly looking to technology, such as Dexcom CGM, for a solution, as studies demonstrate both the health benefits of CGM for T2D and the potential cost savings for health services1-5.

法国报销新闻是世界各国政府和医疗保健提供者越来越意识到T2D诊断率上升对国家医疗保健服务和患者的影响的一部分。政府和医疗保健提供者越来越多地寻求Dexcom CGM等技术的解决方案，因为研究表明CGM对T2D的健康益处以及医疗服务的潜在成本节约1-5。

Dexcom also recently secured reimbursement of its sensors in Germany with health insurance provider KKH for those living with Type 2 diabetes and receiving Basal Oral Therapy..

Dexcom最近还与健康保险提供商KKH合作，为患有2型糖尿病并接受基础口服治疗的患者报销了其在德国的传感器费用。。

“The decision by the French government to offer national reimbursement for Dexcom CGM to those treating their Type 2 diabetes with basal insulin injections is a significant step forward in both the treatment and understanding of Type 2 diabetes on both an individual and societal level,” said Alex Moussa, Senior Vice President and General Manager of Dexcom EMEA & LATAM.

Dexcom EMEA&LATAM高级副总裁兼总经理亚历克斯·穆萨（Alex Moussa）表示：“法国政府决定向那些通过基础胰岛素注射治疗2型糖尿病的患者提供Dexcom CGM的国家报销，这在个人和社会层面上都是对2型糖尿病治疗和理解的重大进步。”。

“We will continue to advocate for widening access to our life-changing technology for those living with Type 2 diabetes. The science and economics are clear: our technology can significantly improve the management of Type 2 diabetes, positively impact the lives of those living with the condition, and lead to cost savings for healthcare services.”.

“我们将继续倡导扩大2型糖尿病患者使用我们改变生活的技术的机会。科学和经济学都很清楚：我们的技术可以显着改善2型糖尿病的管理，对患有这种疾病的患者的生活产生积极影响，并为医疗保健服务节省成本。”。

The management of T2D is a hot topic around the world as diagnoses of the condition continue to steadily grow, with Western European countries seeing some of the fastest growth rates*6. The impact on the lives of those living with the condition is also becoming clearer. A recent, first-of-its-kind survey by Dexcom of those living with T2D in the UK showed that 63% of respondents encountered difficulties managing their diabetes, and 83% of respondents were open to using CGM technology to help manage their T2D7..

T2D的管理是世界各地的热门话题，因为对该病的诊断持续稳步增长，西欧国家的增长速度最快*6。对那些患有这种疾病的人的生活的影响也越来越明显。Dexcom最近对英国T2D患者进行的首次同类调查显示，63%的受访者在管理糖尿病方面遇到困难，83%的受访者愿意使用CGM技术帮助管理T2D7。。

However, while the use of CGM technology to help manage T2D is on the rise, it remains an underutilised technology. The same survey showed that although those living with the condition were keen to turn to technology for a solution, prescribing CGM for T2D is not standard practice among healthcare professionals.

然而，虽然使用CGM技术来帮助管理T2D的人数正在增加，但它仍然是一种未得到充分利用的技术。同一项调查显示，尽管那些患有这种疾病的人热衷于寻求技术解决方案，但为T2D开具CGM并不是医疗保健专业人员的标准做法。

Across the spectrum of T2D users, only 39% had used the technology. With T2D growing worldwide, a willingness among people with T2D to use tech to manage the condition, and growing evidence that CGM usage, such as Dexcom CGM, can improve lives and save money, France's leadership strengthens the case for additional countries to expand access to Dexcom technology for people with Type 2 diabetes..

在T2D用户中，只有39%使用过该技术。随着T2D在全球范围内的增长，T2D患者愿意使用技术来管理病情，以及越来越多的证据表明使用CGM（如Dexcom CGM）可以改善生活和节省资金，法国的领导层加强了其他国家扩大2型糖尿病患者使用Dexcom技术的机会。。

*2017 6059 cases of T2 diabetes per 100,000 people, expected to reach 7079 per 100,000 by 2030.

*2017年，每10万人中有6059例T2型糖尿病，预计到2030年将达到每10万人7079例。

1 Alshannaq H et al Cost-utility of real-time continuous glucose monitoring versus self-monitoring of blood glucose in people with insulin-treated Type II diabetes in France. J Comp Eff Res. 2024; 13(3):e230174. 2 Isitt JJ, et al. Cost-Effectiveness of a Real-Time Continuous Glucose Monitoring System Versus Self-Monitoring of Blood Glucose in People with Type 2 Diabetes on Insulin Therapy in the UK.

1 Alshannaq H等人在法国胰岛素治疗的II型糖尿病患者中实时连续血糖监测与自我血糖监测的成本效用。J Comp Eff Res.2024；13（3）：e230174。2 Isitt JJ等人。实时连续血糖监测系统与英国胰岛素治疗2型糖尿病患者血糖自我监测的成本效益。

Diabetes Ther. 2022; 13(11-12):1875-90. 3 Dexcom, Data on File 2024. 4 Reaven, P. Initiating Continuous Glucose Monitoring (CGM) in Adult-Onset Type 1 and Type 2 Diabetes Reduces Mortality. Presented at ATTD, 2024; March 9th. Florence, Italy. 5 Clark T et al. Diabetes Technol Ther. 2024. doi: 10.1089/dia.2023.0612.

糖尿病治疗。2022年；13（11-12）：1875-90年。3 Dexcom，文件2024中的数据。4 Reaven，P。在成人发病的1型和2型糖尿病中启动连续血糖监测（CGM）可降低死亡率。于2024年在ATTD上提交；3月9日。意大利佛罗伦萨。5 Clark T等人。糖尿病技术。2024年。doi:10.1089/dia.2023.0612。

6 Khan MAB et al J Epidemiol Glob Health. 2020 Mar;10(1):107-111. 7 Dexcom and Censuswide online survey of people living with diabetes (Type 2, their caretakers and healthcare practitioners), conducted in the UK, H1 2024, N=852, PWD = 251, HCP = 351, Caretakers = 250.

6 Khan MAB等人J Epidemiol Glob Health。2020年3月；10（1）：107-111。7 Dexcom和Censuswide对英国糖尿病患者（2型糖尿病患者及其护理人员和医疗保健从业人员）进行的在线调查，2024年上半年，N=852，PWD=251，HCP=351，护理人员=250。

Category: IR

类别：IR

About DexCom, Inc.

关于DexCom，Inc。

DexCom, Inc. empowers people to take real-time control of health through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, Calif., and with operations across Europe and select parts of Asia/Oceania, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom works to simplify and improve diabetes management around the world.

DexCom，Inc.通过创新的连续血糖监测（CGM）系统，使人们能够实时控制健康。Dexcom总部位于加利福尼亚州圣地亚哥，业务遍及欧洲和亚洲/大洋洲的部分地区，已成为糖尿病护理技术的领导者。通过倾听用户、护理人员和提供者的需求，Dexcom致力于简化和改进世界各地的糖尿病管理。

For more information about Dexcom CGM, visit www.dexcom.com..

有关Dexcom CGM的更多信息，请访问www.Dexcom.com。。